Chapter 3 Infectious Diseases Related to Travel
James P. Alexander, Manisha Patel, Steven G. F. Wassilak
Poliovirus (genus Enterovirus) types 1, 2, and 3. Polioviruses are small (27–30 nm), nonenveloped viruses with capsids enclosing a single-stranded, positive-sense RNA genome about 7,500 nucleotides long. Most of the properties of polioviruses are shared with the other enteroviruses.
Fecal-oral or oral transmission. Acute infection involves the oropharynx, gastrointestinal tract, and occasionally the central nervous system.
Before a vaccine was available, infection with poliovirus was common worldwide, with seasonal peaks and epidemics in the summer and fall in temperate areas. The incidence of poliomyelitis in the United States declined rapidly after the licensure of inactivated polio vaccine (IPV) in 1955 and live oral polio vaccine (OPV) in the 1960s. The last cases of indigenously acquired polio in the United States occurred in 1979. The Global Polio Eradication Initiative (GPEI) subsequently eliminated polio in the Americas, where the last wild poliovirus (WPV)–associated polio case was detected in 1991. In January 2000, a change in vaccination policy in the United States from use of live OPV to exclusive use of IPV eliminated the 8–10 vaccine-associated paralytic poliomyelitis (VAPP) cases that had occurred annually since the introduction of OPV in the 1960s.
GPEI has built upon the success in the Americas and made great progress in eradicating WPVs, reducing the number of reported polio cases worldwide by more than 99% since the mid-1980s. As of April 2016, WPV circulation has never been interrupted in only 2 countries: Afghanistan and Pakistan. Because of polio eradication efforts, the number of countries where travelers are at risk for polio has decreased dramatically. The last documented case of WPV-associated paralysis in a US resident traveling abroad occurred in 1986 in a 29-year-old vaccinated adult who had been traveling in South and Southeast Asia. In 2005, an unvaccinated US adult traveling abroad acquired VAPP after contact with an infant recently vaccinated with OPV.
In spite of progress made in eradicating WPVs globally, polio-free countries remain at risk for imported WPV cases and outbreaks, and travelers to some countries are at risk for exposure to WPV. During 2003–2013, northern Nigeria served as a reservoir for the spread of WPV into 26 previously polio-free countries, many of which were part of a “WPV importation belt” extending across sub-Saharan Africa from the west coast to the Horn of Africa in the east. With the intensification of polio eradication activities in Nigeria and neigh-boring countries during 2012–2014, outbreaks were controlled and endemic transmission in Nigeria was interrupted. From 2012 through early 2014, imported WPV from Pakistan was found in some sewage samples taken in Egypt, Israel, and the West Bank and Gaza (without any identified polio cases) and caused outbreaks in Iraq and Syria—all of which were controlled by July 2015. In addition to these risks, travelers are also at risk for contracting polio from cases and outbreaks of vaccine-derived poliovirus (VDPV), which can develop and circulate in areas with low vaccination coverage where OPV is used.
For additional information on the status of polio eradication efforts, countries or areas with active WPV or VDPV circulation, and vaccine recommendations, consult the travel notices on the CDC Travelers’ Health website (www.cdc.gov/travel) or the GPEI website (www.polioeradication.org).
Clinical manifestations of poliovirus infection range from asymptomatic (most infections) to symptomatic, including acute flaccid paralysis of a single limb to quadriplegia, respiratory failure, and rarely, death.
The diagnosis is made by identifying poliovirus in clinical specimens (usually stool) obtained from an acutely ill patient. Poliovirus may be detected by cell culture followed by identification using plaque reduction neutralization tests or PCR. Poliovirus may also be identified by direct nucleic acid amplification from stool specimens followed by genomic sequencing to confirm the genotype and determine the likely geographic origin. Shedding in fecal specimens can be intermittent, but usually poliovirus can be detected for up to 4 weeks after onset of illness. During the first 3–10 days of the illness, poliovirus can also be detected from oropharyngeal specimens. Poliovirus is rarely detected in the blood or cerebrospinal fluid. Polio is a nationally notifiable disease.
Only treatment for symptoms is available, ranging from pain and fever relief to intubation and mechanical ventilation for patients with respiratory insufficiency.
RECOMMENDATIONS FOR HEALTH PROTECTION
In the United States, infants and children should be vaccinated against polio as part of a routine immunization series (see Infants and Children below). Polio vaccination is recommended for all travelers to countries with WPV or VDPV circulation. Countries are considered to have WPV or VDPV circulation if they have evidence during the previous 12 months of ongoing endemic circulation (WPV only), a polio outbreak, or environmental evidence (through sewage sampling) of WPV or VDPV circulation. For additional information on countries with WPV or VDPV circulation and vaccine recommendations, consult the travel notices on the CDC Travelers’ Health website (www.cdc.gov/travel) or the weekly update of reported WPV and VDPV cases at the GPEI website (www.polioeradication.org/Dataandmonitoring/Poliothisweek.aspx).
Before traveling to areas that have WPV or VDPV circulation, travelers should ensure that they have completed the recommended age-appropriate polio vaccine series and that adults have received a single lifetime IPV booster dose. In addition, CDC recommends a single lifetime IPV booster dose for certain adult travelers to some countries that border areas with WPV circulation. These recommendations are based on evidence of historical cross-border transmission. These recommendations apply only to travelers with a high risk of exposure to someone with imported WPV infection. These travelers would include those working in health care settings, refugee camps, or other humanitarian aid settings. Since the situation is dynamic, refer to the CDC Travelers’ Health website destination pages for the most up-to-date polio vaccine recommendations (wwwnc.cdc.gov/travel/destinations/list).
To eliminate the risk for VAPP, IPV has been the only polio vaccine available in the United States since 2000; however, OPV continues to be used in many countries and for global polio eradication activities. For complete information on recommendations for poliomyelitis vaccination, consult the Advisory Committee on Immunization Practices recommendations website (www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/polio.html) and the World Health Organization position paper on poliovirus vaccines (www.who.int/wer/2016/wer9112/en).
In May 2014, the World Health Organization (WHO) declared the international spread of polio to be a public health emergency of international concern under the authority of the International Health Regulations (2005). To prevent further spread of disease, WHO issued temporary polio vaccine recommendations for long-term travelers (staying >4 weeks) and residents departing from countries with WPV transmission (“exporting WPV” or “infected with WPV”). In November 2015, these recommendations were extended to long-term travelers (staying >4 weeks) and residents departing from countries with VDPV transmission (“infected with VDPV”). Clinicians should be aware that long-term travelers and residents may be required to show proof of polio vaccination when departing from these countries. All polio vaccination administration should be documented on an International Certificate of Vaccination or Prophylaxis (ICVP). The polio vaccine must be received between 4 weeks and 12 months before the date of departure from the polio-affected country. Country requirements may change, so clinicians should check for updates on the CDC Travelers’ Health website. Refer to the Clinical Update: Interim CDC Guidance for Travel to and from Countries Affected by the New Polio Vaccine Requirements (wwwnc.cdc.gov/travel/news-announcements/polio-guidance-new-requirements) for a list of affected countries, guidance on meeting the vaccination requirements, and instructions on how to order and fill out the ICVP.
INFANTS AND CHILDREN
In the United States, all infants and children should receive 4 doses of IPV at ages 2, 4, and 6–18 months and 4–6 years. The final dose should be administered at age ≥4 years, regardless of the number of previous doses, and should be given ≥6 months after the previous dose. A fourth dose in the routine IPV series is not necessary if the third dose was administered at age ≥4 years and ≥6 months after the previous dose. If the routine series cannot be administered within the recommended intervals before protection is needed, the following alternatives are recommended:
- The first dose should be given to infants at age ≥6 weeks.
- The second and third doses should be administered ≥4 weeks after the previous doses.
- The minimum interval between the third and fourth doses is 6 months.
If the age-appropriate series is not completed before departure, the remaining IPV doses to complete a full series should be administered when feasible, at the intervals recommended above.
Adults who are traveling to areas where WPV or VDPV is actively circulating and who are unvaccinated, incompletely vaccinated, or whose vaccination status is unknown should receive a series of 3 doses: 2 doses of IPV administered at an interval of 4–8 weeks; a third dose should be administered 6–12 months after the second. If 3 doses of IPV cannot be administered within the recommended intervals before protection is needed, the following alternatives are recommended:
- If >8 weeks is available before protection is needed, 3 doses of IPV should be administered ≥4 weeks apart.
- If <8 weeks but >4 weeks is available before protection is needed, 2 doses of IPV should be administered ≥4 weeks apart.
- If <4 weeks is available before protection is needed, a single dose of IPV is recommended.
If <3 doses are administered, the remaining IPV doses to complete a 3-dose series should be administered when feasible, at the intervals recommended above, if the person remains at increased risk for poliovirus exposure.
Adults who have completed a routine series of polio vaccine are considered to have lifelong immunity to poliomyelitis, but data on duration of immunity are lacking. As a precaution, adults (≥18 years of age) who are traveling to areas where WPV or VDPV is actively circulating and who have received a routine series with either IPV or OPV in childhood should receive another dose of IPV before departure. For adults, available data do not indicate the need for more than a single lifetime booster dose with IPV.
INTERNATIONAL ADOPTION OF CHILDREN
The international adoption of children from countries or areas where WPV or VDPV is actively circulating is a special situation. International adoptees might not have completed a primary vaccination series against polio and might not have received a dose of polio vaccine before departure. Thus, there is a small risk that they might be infected with WPV or VDPV and remain infectious upon entry into the United States and potentially transmit to US household members and caregivers. So, as a measure of prudence, the polio vaccination status of all household members and caregivers of international adoptees whose origin is a country with active WPV or VDPV circulation should be assessed before the entry of the child into the United States. Those who are unvaccinated, incompletely vaccinated, or whose vaccination status is unknown should be brought up-to-date. Adults who have completed the primary series should consider a one-time booster of IPV as well.
VACCINE SAFETY AND ADVERSE REACTIONS
Minor local reactions (pain and redness) can occur after IPV administration. No serious adverse reactions to IPV have been documented. IPV should not be administered to people who have experienced a severe allergic reaction (such as anaphylaxis) after a previous dose of IPV or after receiving streptomycin, polymyxin B, or neomycin, which IPV contains in trace amounts; hypersensitivity reactions can occur after IPV administration among people sensitive to these 3 antibiotics.
PREGNANCY AND BREASTFEEDING
If a pregnant woman is unvaccinated or incompletely vaccinated and requires immediate protection against polio because of planned travel to a country or area where WPV or VDPV is actively circulating, IPV can be administered as recommended for adults. Breastfeeding is not a contraindication to administration of polio vaccine to an infant or mother.
PRECAUTIONS AND CONTRAINDICATIONS
IPV may be administered to people with diarrhea. Minor upper respiratory illnesses with or without fever, mild to moderate local reactions to a previous dose of IPV, current antimicrobial therapy, and the convalescent phase of acute illness are not contraindications for vaccination.
IPV may be administered safely to immunocompromised travelers and their household contacts. Although a protective immune response cannot be ensured, IPV might confer some protection to the immunocompromised person. People with certain primary immunodeficiency diseases should not be given OPV and should avoid contact with excreted OPV virus (such as exposure to a child vaccinated with OPV in the previous 6 weeks); however, this situation no longer occurs in the United States unless a child receives OPV overseas.
CDC website: www.cdc.gov/polio
- CDC. Immunization schedules. Atlanta: CDC; 2016 [cited 2016 Sep. 25]. Available from: http://www.cdc.gov/vaccines/schedules/index.html.
- CDC. Progress toward polio eradication—worldwide, 2014–2015. MMWR Morb Mortal Wkly Rep. 2015 May 22;64(19):527–31.
- CDC. Progress toward poliomyelitis eradication— Nigeria, January 2014–July 2015. MMWR Morb Mortal Wkly Rep. 2015 Aug 21;64(32):878–82.
- CDC. Update on vaccine-derived polioviruses— worldwide, January 2014–March 2015. MMWR Morb Mortal Wkly Rep. 2015 Jun 19;64(23):640–6.
- CDC. Updated recommendations of the Advisory Committee on Immunization Practices (ACIP) regarding routine poliovirus vaccination. MMWR Morb Mortal Wkly Rep. 2009 Aug 7;58(30):829–30.
- Prevots DR, Burr RK, Sutter RW, Murphy TV. Poliomyelitis prevention in the United States. Updated recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2000 May 9;49(RR-5):1–22.
- Sutter RW, Kew OM, Cochi SL, Aylward RB. Poliovirus vaccine—live. In: Plotkin SA, Orenstein WA, Offit PA, editors. Vaccines. 6th ed. Philadelphia: Saunders Elsevier; 2012. p. 598–645.
- Vidor E, Plotkin SA. Poliovirus vaccine—inactivated. In: Plotkin SA, Orenstein WA, Offit PA, editors. Vaccines. 6th ed. Philadelphia: Saunders Elsevier; 2012. pp. 573–97.
- World Health Organization. Polio vaccines: WHO position paper—March, 2016. Wkly Epidemiol Rec. 2016 Mar 25;91(12):145–68.
- World Health Organization. Wild poliovirus weekly update. World Health Organization; 2014 [cited 2016 Sep. 25]. Available from: http://www.polioeradication.org/Dataandmonitoring/Poliothisweek.aspx.
- Page created: May 31, 2017
- Page last updated: May 31, 2017
- Page last reviewed: May 31, 2017
- Content source: